Clinical Trial Update: Vaginal DHEA for Women After Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating vaginal DHEA for vaginal dryness and related quality-of-life symptoms in women after breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Urinary Incontinence
• Vaginal Dryness

Drugs mentioned

• Intrarosa (prasterone) vaginal insert (prasterone)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Vaginal Dryness, Breast Cancer | Phase 2, Phase 3 | Status: WITHDRAWN